<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958396</url>
  </required_header>
  <id_info>
    <org_study_id>201504056</org_study_id>
    <nct_id>NCT03958396</nct_id>
  </id_info>
  <brief_title>Remifentanil in Children With Obstructive Sleep Apnea</brief_title>
  <acronym>ROSA</acronym>
  <official_title>The Pharmacokinetic and Pharmacodynamics Profiles of Remifentanil in Children With Obstructive Sleep Apnea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation tested the hypothesis that children with obstructive sleep apnea have an
      increased pharmacodynamic sensitivity to the miotic and respiratory depressant effects of the
      prototypic Î¼-opioid agonist remifentanil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel group study comparing patients with obstructive sleep apnea undergoing tonsillectomy or tonsillectomy and adenoidectomy to controls with no history of obstructive sleep apnea undergoing general anesthesia for any procedure. The study will be conducted in the patient's preoperative holding area room. Two intravenous catheters will be placed, one for a remifentanil infusion and one for blood draws to measure the blood concentration of remifentanil. Patients will have standard ASA monitors placed with vital signs monitored on a portable monitor, and a remifentanil infusion will be started. Blood draws will be taken at seven time points: zero, one, two, four, six, ten and fifteen minutes. Concomitantly, recordings of end tidal CO2, respiratory rate, and pupil diameter will be made at the seven time points.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in end-expired carbon dioxide from baseline over time - OSA Group</measure>
    <time_frame>Approximately 1 hour before surgery - Measurements taken at 0, 1, 2, 4, 6, 10 &amp; 15 minutes following remefentanil infusion</time_frame>
    <description>End-expired carbon dioxide monitoring using bedside monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in end-expired carbon dioxide from baseline over time - Control (non-OSA) Group</measure>
    <time_frame>Approximately 1 hour before surgery - Measurements taken at 0, 1, 2, 4, 6, 10 &amp; 15 minutes following remefentanil infusion</time_frame>
    <description>End-expired carbon dioxide monitoring using bedside monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory rate from baseline over time - OSA Group</measure>
    <time_frame>Approximately 1 hour before surgery - Measurements taken at 0, 1, 2, 4, 6, 10 &amp; 15 minutes following remefentanil infusion</time_frame>
    <description>Respiratory monitoring was performed using nasal cannula</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory rate from baseline over time - Control (non-OSA) Group</measure>
    <time_frame>Approximately 1 hour before surgery - Measurements taken at 0, 1, 2, 4, 6, 10 &amp; 15 minutes following remefentanil infusion</time_frame>
    <description>Respiratory monitoring was performed using nasal cannula</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pupil diameter from baseline over time - OSA Group</measure>
    <time_frame>Approximately 1 hour before surgery - Measured continuously and averaged into 10-s bins following remefentanil infusion</time_frame>
    <description>Dark adapted infrared pupillometry performed using binocular infrared pupilometer mounted in light occlusive goggles sampling at 100 Hz.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pupil diameter from baseline over time - Control (non-OSA) Group</measure>
    <time_frame>Approximately 1 hour before surgery - Measured continuously and averaged into 10-s bins following remefentanil infusion</time_frame>
    <description>Dark adapted infrared pupillometry performed using binocular infrared pupilometer mounted in light occlusive goggles sampling at 100 Hz.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remifentanil plasma concentration - OSA Group</measure>
    <time_frame>Approximately 1 hour before surgery - Blood draws at 0, 1, 2, 4, 6, 10 &amp; 15 minutes following remefentanil infusion</time_frame>
    <description>3ml blood draw</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remifentanil plasma concentration - Contro (non-OSA) Group</measure>
    <time_frame>Approximately 1 hour before surgery - Blood draws at 0, 1, 2, 4, 6, 10 &amp; 15 minutes following remefentanil infusion</time_frame>
    <description>3ml blood draw</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>OSA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a) Children 8-14 years old, b) ASA physical status 1or 2, c) undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (non-OSA) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a) Children 8-14 years old, b) ASA physical status 1or 2, c) no known obstructive sleep apnea presenting for any procedure requiring general anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Infusion</intervention_name>
    <description>15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min</description>
    <arm_group_label>Control (non-OSA) Group</arm_group_label>
    <arm_group_label>OSA Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        OSA Group:

        Inclusion Criteria:

          -  8-14 years old

          -  ASA physical status 1 or 2

          -  undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive
             sleep apnea

        Exclusion Criteria:

          -  Inability to cooperate with study requirements (IV placement, sitting quietly, wearing
             goggles, etc.)

        Control (Non-OSA) Group:

        Inclusion Criteria:

          -  8-14 years old

          -  ASA physical status 1 or 2

          -  no known obstructive sleep apnea presenting for any procedure requiring general
             anesthtic

        Exclusion Criteria:

          -  Inability to cooperate with study requirements (IV placement, sitting quietly, wearing
             goggles, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anshuman Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <results_reference>
    <citation>Brown KA. Outcome, risk, and error and the child with obstructive sleep apnea. Paediatr Anaesth. 2011 Jul;21(7):771-80. doi: 10.1111/j.1460-9592.2011.03597.x. Epub 2011 May 3. Review.</citation>
    <PMID>21539679</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, Schechter MS, Ward SD, Sheldon SH, Shiffman RN, Lehmann C, Spruyt K; American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012 Sep;130(3):e714-55. doi: 10.1542/peds.2012-1672. Epub 2012 Aug 27. Review.</citation>
    <PMID>22926176</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhattacharyya N, Lin HW. Changes and consistencies in the epidemiology of pediatric adenotonsillar surgery, 1996-2006. Otolaryngol Head Neck Surg. 2010 Nov;143(5):680-4. doi: 10.1016/j.otohns.2010.06.918.</citation>
    <PMID>20974339</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

